Just weeks after IntraBio secured a label expansion for its lead asset Aqneursa, Japanese drugmaker Shionogi is moving in to take the reins. Shionogi is handing over $2 billion for the Austin, Texas-based commercial biotech, in a deal that—in addition to Aqneursa—will grant access to IntraBio’s rare disease expertise and pipeline. The acquisition builds on Shionogi’s plans to diversify beyond its anti-infectious disease drug base and to beef up its budding rare disease unit, which was founded

Oct. 19, 2026 -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that its partner, the University of Oklahoma (OU), has received $2.9 million in funding from the National Cancer Institute (NCI) to study, in clinical trials, whether RedHill's opaganib[1], given after CAR (chimeric antigen receptor) T-cell therapy, may help immune cells fight cancer more effectively. The five-year, $2.9 million grant from the NCI is planne

TREMFYA maintained combined fistula remission through Week 48 across both maintenance dose regimens, including an increase from 28% at Week 24 to 35% at Week 48 in the 100 mg dose group These findings build on the Phase 3 clinical program, demonstrating efficacy in a dedicated, randomized, placebo-controlled trial in patients with this debilitating and challenging manifestation of Crohn's disease Oct. 19, 2026 -- Johnson & Johnson (NYSE: JNJ) today announced one-year results from the Phase 3 FU

- Clearance enables initiation of SHIELD-AL, a pivotal study in newly diagnosed patients with lambda AL amyloidosis - Investigational oral light chain stabilizer to be evaluated as an add-on to standard-of-care plasma cell-directed therapy Oct. 19, 2026 -- Protego Biopharma, Inc., a clinical-stage biotechnology company developing small molecule therapies for protein misfolding diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IN

Positive Phase 1 data were previously presented in an oral session at ASCO 2026 Emi-Le received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the proposed treatment of patients with locally advanced, recurrent or metastatic ACC with solid histology or high-grade transformation Oct. 19, 2026 -- Servier today announced the first patients have been dosed in the pivotal Phase 2 cohort (EMBLEM-1) of a Phase 1/2 study of Emiltatug Ledadotin (Emi-Le) in solid tu

OptimUM-01 and OptimUM-02 data supports the broad potential of darovasertib plus crizotinib to drive meaningful clinical benefits for patients with metastatic uveal melanoma, irrespective of HLA-A*02:01 allele status or line of therapy OptimUM-01 data demonstrates encouraging clinical activity from darovasertib combined with crizotinib in both treatment-naïve (7.4 month PFS, 27.1 month mOS, n=13) and heavily pretreated HLA-A*02:01-positive metastatic uveal melanoma, including in 2L patients foll

Financing co-led by new investors Bain Capital Life Sciences, Forbion and Novo Holdings, with strong participation from additional new and existing investors Proceeds to advance MC2 receptor antagonist OMS1620 through Phase 2 development and generate early clinical data for SLC15A4 inhibitor 15 October 2026 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company developing small molecule therapeutics against highly validated target ecosystems, today announced an oversubscribed

Immunocore announces first patient dosed in the Phase 1 trial ofIMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetes The Phase 1 trial will assess the safety and clinical activity of IMC-S118AI in HLA-A*02:01-positive patients with type 1 diabetes Preclinical data supporting unique mechanism of action recently published in Science Advances 15 October 2026 Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotech

Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinica

New designation expands on first Fast Track Designation in TMB-H colorectal cancer and is supported by monotherapy responses across multiple tumor types in the STARt-001 study Invikafusp alfa believed to be first immuno-oncology T-cell agonist to receive Fast Track Designation in a biomarker-defined, tissue-agnostic indication New designation supported by updated Phase 2 data in this population, which will be featured in an oral presentation at the European Society for Medical Oncology (ESMO) Co